A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer

NCT01647789 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: CFG920

Sponsor

Novartis Pharmaceuticals